Neurology News

An early return to school and other life activities following a concussion were associated with a lower symptom burden and faster recovery among children and adolescents, researchers reported in JAMA Network Open.

The FDA issued a complete response letter on the accelerated approval of donanemab for treatment of early symptomatic Alzheimer’s disease, citing the limited number of patients with longer drug exposure data.

Hormone therapy may promote better memory and cognitive function and larger brain volumes among women carrying APOE4, a genetic risk factor for Alzheimer’s disease.

The most common neurological manifestations of COVID-19 for individuals living in Saudi Arabia were headache, changes in smell and taste, muscle pain, loss of consciousness and seizures, which were similar to global reports.

Cycle Pharmaceuticals announced that the FDA has approved its Tascenso ODT, a bioequivalent to Gilenya, or generic fingolimod, for patients with relapsing forms of MS.

Among midlife and older women in China, some of their own and their spouse’s adverse childhood experiences — mediated to some extent by depression — were associated with poorer cognitive function, according to study data.

Sleep disturbances were found to be prevalent throughout the course of psychosis, and different psychosis stages showed shared and distinct abnormalities, researchers reported in JAMA Psychiatry.

The FDA has granted fast track designation to Avidity Biosciences Inc. for its novel RNA therapeutic AOC 1020, an antibody oligonucleotide conjugate being studied for the treatment of facioscapulohumeral muscular dystrophy.

U.K.-based biotechnology company Pheno Therapeutics announced it has entered into an exclusive worldwide license agreement with Belgian-based biopharmaceutical company UCB to deliver new therapeutics for neurodegenerative disease.

The ACP has proposed a new process to streamline specialty referrals — a step that experts have called critical to fixing a massive issue in health care — but questions remain about the plan’s feasibility.